MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Day One Biopharmaceuticals Inc

Cerrado

SectorSalud

6.61 1.54

Resumen

Variación precio

24h

Actual

Mínimo

6.38

Máximo

6.72

Métricas clave

By Trading Economics

Ingresos

30M

-36M

Ventas

1.6M

31M

BPA

-0.35

Margen de beneficio

-117.018

Empleados

181

EBITDA

24M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+332.92% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-163M

641M

Apertura anterior

5.07

Cierre anterior

6.61

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

163 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jul 2025, 23:09 UTC

Ganancias

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Charlas de Mercado

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Ganancias

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Charlas de Mercado

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Charlas de Mercado

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Charlas de Mercado

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Charlas de Mercado

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Charlas de Mercado

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Charlas de Mercado

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Charlas de Mercado

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Adquisiciones, fusiones, absorciones

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Ganancias

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Charlas de Mercado

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Charlas de Mercado

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Charlas de Mercado

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

332.92% repunte

Estimación a 12 meses

Media 28.14 USD  332.92%

Máximo 36 USD

Mínimo 20 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

163 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.